User login
Key clinical point: Risankizumab showed consistent long-term efficacy in patients with active psoriatic arthritis (PsA) regardless of baseline demographic, disease characteristics, and prior medication use.
Major finding: At week 24, a higher number of patients receiving risankizumab vs placebo achieved ≥ 20% improvement in the American College of Rheumatology response (ACR20; 46.3%-60.1% vs 15.5%-36.2%) despite varying demographic and disease characteristics. At week 52, similar proportions of patients who were randomized to risankizumab (48.6%-75.8%) or who switched from placebo to risankizumab (43.7%-63.9%) achieved ACR20.
Study details: This post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 trials included 1235 patients with active PsA and prior inadequate response or intolerance to conventional synthetic or biologic disease-modifying antirheumatic drugs who received risankizumab or placebo with crossover to risankizumab at week 24.
Disclosures: This study was funded by AbbVie. Four authors declared being employees of and holding stocks or stock options with AbbVie. The other authors declared having ties with AbbVie and various sources.
Source: Merola JF, Armstrong A, Khattri S, et al. Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: A post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials. J Dermatolog Treat. 2024;35:2342383. Source
Key clinical point: Risankizumab showed consistent long-term efficacy in patients with active psoriatic arthritis (PsA) regardless of baseline demographic, disease characteristics, and prior medication use.
Major finding: At week 24, a higher number of patients receiving risankizumab vs placebo achieved ≥ 20% improvement in the American College of Rheumatology response (ACR20; 46.3%-60.1% vs 15.5%-36.2%) despite varying demographic and disease characteristics. At week 52, similar proportions of patients who were randomized to risankizumab (48.6%-75.8%) or who switched from placebo to risankizumab (43.7%-63.9%) achieved ACR20.
Study details: This post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 trials included 1235 patients with active PsA and prior inadequate response or intolerance to conventional synthetic or biologic disease-modifying antirheumatic drugs who received risankizumab or placebo with crossover to risankizumab at week 24.
Disclosures: This study was funded by AbbVie. Four authors declared being employees of and holding stocks or stock options with AbbVie. The other authors declared having ties with AbbVie and various sources.
Source: Merola JF, Armstrong A, Khattri S, et al. Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: A post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials. J Dermatolog Treat. 2024;35:2342383. Source
Key clinical point: Risankizumab showed consistent long-term efficacy in patients with active psoriatic arthritis (PsA) regardless of baseline demographic, disease characteristics, and prior medication use.
Major finding: At week 24, a higher number of patients receiving risankizumab vs placebo achieved ≥ 20% improvement in the American College of Rheumatology response (ACR20; 46.3%-60.1% vs 15.5%-36.2%) despite varying demographic and disease characteristics. At week 52, similar proportions of patients who were randomized to risankizumab (48.6%-75.8%) or who switched from placebo to risankizumab (43.7%-63.9%) achieved ACR20.
Study details: This post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 trials included 1235 patients with active PsA and prior inadequate response or intolerance to conventional synthetic or biologic disease-modifying antirheumatic drugs who received risankizumab or placebo with crossover to risankizumab at week 24.
Disclosures: This study was funded by AbbVie. Four authors declared being employees of and holding stocks or stock options with AbbVie. The other authors declared having ties with AbbVie and various sources.
Source: Merola JF, Armstrong A, Khattri S, et al. Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: A post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials. J Dermatolog Treat. 2024;35:2342383. Source